While GCGR/GLP-1R dual agonists like cotadutide and survodutide have advanced into clinical studies, the investigative focus remains largely on diabetes, obesity, and liver fibrosis (10–12). This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.